The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | The role of non-covalent BTKis in the era of covalent BTKis for B-cell malignancies
Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, discusses the role of non-covalent BTK inhibitors (BTKis) in the era of covalent BTKis, highlighting their role in diseases such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Non-covalent BTKis offer a new treatment option for patients who have developed resistance due to mutations in the BTK binding site. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
